154357-42-3 Usage
Description
(S)-(-)-Nadifloxacin is a potent anti-bacterial agent specifically designed to combat multidrug-resistant Staphylococcus aureus (MRSA). Derived from 6-Fluoro-2-methylquinoline (F595900), a quinoline derivative, it also exhibits properties of a highly potent thrombin receptor antagonist. This dual functionality positions (S)-(-)-Nadifloxacin as a valuable compound in the medical field for treating bacterial infections and potentially managing thrombin-related conditions.
Uses
Used in Pharmaceutical Industry:
(S)-(-)-Nadifloxacin is used as an anti-bacterial agent for the treatment of multidrug-resistant Staphylococcus aureus (MRSA) infections. Its effectiveness against MRSA makes it a crucial component in the development of new antibiotics to address the growing concern of antibiotic resistance.
Additionally, due to its thrombin receptor antagonist properties, (S)-(-)-Nadifloxacin can be used as a potential therapeutic agent for conditions related to thrombin overactivity, such as deep vein thrombosis, pulmonary embolism, and other clot-related disorders. This application is still under investigation and requires further research to fully understand its potential benefits and limitations.
Check Digit Verification of cas no
The CAS Registry Mumber 154357-42-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,4,3,5 and 7 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 154357-42:
(8*1)+(7*5)+(6*4)+(5*3)+(4*5)+(3*7)+(2*4)+(1*2)=133
133 % 10 = 3
So 154357-42-3 is a valid CAS Registry Number.
154357-42-3Relevant articles and documents
Structure-retention relationship for enantioseparation of selected fluoroquinolones
Hassan, Rasha M.,Yehia, Ali M.,Saleh, Ola A.,El-Azzouny, Aida A.,Aboul-Enein, Hassan Y.
, p. 828 - 836 (2018/04/10)
Fluoroquinolones are popular class of antibiotics with distinct chemical functionality. Most of them are ampholytes with one chiral center. Stereogeneic center is located either in the side ring of Gatifloxacin (GFLX) or in the quinolone core of Ofloxacin (OFLX). These two amphoteric fluoroquinolones have terminal amino groups in common. The unusual Nadifloxacin (NFLX) is an acidic fluoroquinolone with a core chiral center. Owing to chirality and functionality differences among GFLX, OFLX, and NFLX, we mapped these enantiomers onto structure-retention relationship. Amount of acetic acid modifier was studied in screened mobile phase and cellulose tris(3-chloro-4-methyl phenyl carbamate) (Lux cellulose-2) stationary phase. Experimental design of acetic acid% along with column temperature have been applied. Resolution and enantioselectivity have been related to structural features of the studied enantiomers. High amount of acid (0.4%) was optimum for the separation of either side chirality with a proximate amino group (GFLX) or core chirality without basic functionality (NFLX), while low amount (0.2%) is optimum for core chiral center with distal amino group (OFLX). Temperature has no significant effect on resolution and retention of enantiomers except for OFLX. Enantio-retention explains possible chiral selective and nonselective interactions. The proposed methods have been validated for pharmaceutical analyses.
